Laboratory 1 presented the data as the ratio of BCR-ABL to beta2 microglobulin mRNA; laboratory 2 presented the data as the log reduction from their standard value of mean CML patient BCR-ABL levels prior to commencement of treatment, without providing an internal reference standard. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.